DES versus Tamoxifen in Advanced Breast Cancer

L. V.A.M. Beex, G. F.F.M. Pieters, A. G.H. Smals, A. J.M. Koenders, Th J. Benraad, P. W.C. Kloppenborg, Christian Jacquot, Rosalinda Graterol, Jean Bariety, Loïc Capron, Jean Noël Fiessinger, Ian Tannock, Norman Boyd, Roy Clark, Merrill I. Feldman, James N. Ingle

Research output: Contribution to journalLetter

10 Citations (Scopus)

Abstract

To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

Original languageEnglish (US)
Pages (from-to)1041-1043
Number of pages3
JournalNew England Journal of Medicine
Volume304
Issue number17
DOIs
StatePublished - Apr 23 1981

Fingerprint

Diethylstilbestrol
Tamoxifen
Breast Neoplasms
Neoplasms
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Beex, L. V. A. M., Pieters, G. F. F. M., Smals, A. G. H., Koenders, A. J. M., Benraad, T. J., Kloppenborg, P. W. C., ... Ingle, J. N. (1981). DES versus Tamoxifen in Advanced Breast Cancer. New England Journal of Medicine, 304(17), 1041-1043. https://doi.org/10.1056/NEJM198104233041714

DES versus Tamoxifen in Advanced Breast Cancer. / Beex, L. V.A.M.; Pieters, G. F.F.M.; Smals, A. G.H.; Koenders, A. J.M.; Benraad, Th J.; Kloppenborg, P. W.C.; Jacquot, Christian; Graterol, Rosalinda; Bariety, Jean; Capron, Loïc; Fiessinger, Jean Noël; Tannock, Ian; Boyd, Norman; Clark, Roy; Feldman, Merrill I.; Ingle, James N.

In: New England Journal of Medicine, Vol. 304, No. 17, 23.04.1981, p. 1041-1043.

Research output: Contribution to journalLetter

Beex, LVAM, Pieters, GFFM, Smals, AGH, Koenders, AJM, Benraad, TJ, Kloppenborg, PWC, Jacquot, C, Graterol, R, Bariety, J, Capron, L, Fiessinger, JN, Tannock, I, Boyd, N, Clark, R, Feldman, MI & Ingle, JN 1981, 'DES versus Tamoxifen in Advanced Breast Cancer', New England Journal of Medicine, vol. 304, no. 17, pp. 1041-1043. https://doi.org/10.1056/NEJM198104233041714
Beex LVAM, Pieters GFFM, Smals AGH, Koenders AJM, Benraad TJ, Kloppenborg PWC et al. DES versus Tamoxifen in Advanced Breast Cancer. New England Journal of Medicine. 1981 Apr 23;304(17):1041-1043. https://doi.org/10.1056/NEJM198104233041714
Beex, L. V.A.M. ; Pieters, G. F.F.M. ; Smals, A. G.H. ; Koenders, A. J.M. ; Benraad, Th J. ; Kloppenborg, P. W.C. ; Jacquot, Christian ; Graterol, Rosalinda ; Bariety, Jean ; Capron, Loïc ; Fiessinger, Jean Noël ; Tannock, Ian ; Boyd, Norman ; Clark, Roy ; Feldman, Merrill I. ; Ingle, James N. / DES versus Tamoxifen in Advanced Breast Cancer. In: New England Journal of Medicine. 1981 ; Vol. 304, No. 17. pp. 1041-1043.
@article{aa3fff4586684658bea1da23fb636531,
title = "DES versus Tamoxifen in Advanced Breast Cancer",
abstract = "To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.",
author = "Beex, {L. V.A.M.} and Pieters, {G. F.F.M.} and Smals, {A. G.H.} and Koenders, {A. J.M.} and Benraad, {Th J.} and Kloppenborg, {P. W.C.} and Christian Jacquot and Rosalinda Graterol and Jean Bariety and Lo{\"i}c Capron and Fiessinger, {Jean No{\"e}l} and Ian Tannock and Norman Boyd and Roy Clark and Feldman, {Merrill I.} and Ingle, {James N.}",
year = "1981",
month = "4",
day = "23",
doi = "10.1056/NEJM198104233041714",
language = "English (US)",
volume = "304",
pages = "1041--1043",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - DES versus Tamoxifen in Advanced Breast Cancer

AU - Beex, L. V.A.M.

AU - Pieters, G. F.F.M.

AU - Smals, A. G.H.

AU - Koenders, A. J.M.

AU - Benraad, Th J.

AU - Kloppenborg, P. W.C.

AU - Jacquot, Christian

AU - Graterol, Rosalinda

AU - Bariety, Jean

AU - Capron, Loïc

AU - Fiessinger, Jean Noël

AU - Tannock, Ian

AU - Boyd, Norman

AU - Clark, Roy

AU - Feldman, Merrill I.

AU - Ingle, James N.

PY - 1981/4/23

Y1 - 1981/4/23

N2 - To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

AB - To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

UR - http://www.scopus.com/inward/record.url?scp=0019435772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019435772&partnerID=8YFLogxK

U2 - 10.1056/NEJM198104233041714

DO - 10.1056/NEJM198104233041714

M3 - Letter

C2 - 7010171

AN - SCOPUS:0019435772

VL - 304

SP - 1041

EP - 1043

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 17

ER -